Table 3 E4 analysis- proportion of adherence to the different subscores among all participating prisons (n = 109)

Information-Education-Communication

0

0

0

0

• Availability of Information/education at entry or during prison stay

15 (88.2)

28 (100.0)

3 (10.3)

13 (37.1)

<10 ⁻³

• Peer education programs available

4 (23.5)

2 (7.1)

4 (13.8)

1 (2.9)

0.07

• Availability of clean injecting equipment + condoms

0

0

0

0

Testing – Counseling

0

0

0

0

• Testing for HIV, HBV, HCV systematically proposed at entry (RC) and during prison stay (all prisons)

3 (17.7)

11 (39.3)

8 (27.6)

35 (100.0)

<10 ⁻³

• Availability of clean injecting equipment + condoms

0

0

0

0

Condoms - Lubricants

9 (52.9)

8 (28.6)

2 (6.9)

0 (0.0)

0.002 ł

• Condoms available in various locations

12 (70.6)

14 (50.0)

14 (48.3)

0 (0.0)

0.29 ł

• Water-based lubricants available

13 (76.5)

23 (82.1)

6 (20.7)

0 (0.0)

<10-3 ł

• Male condoms and lubricants accessible and female condoms accessible for prisons with female prisoners

14 (82.4)

14 (50.0)

13 (44.8)

0 (0.0)

0.04 ł

Opioid Substitution Therapy

4 (23.5)

6 (21.4)

7 (24.1)

5 (14.3)

0.66

• Induction at entry (RC) + induction during prison stay + continuity of OST at entry (all prisons)

11 (64.7)

20 (71.4)

24 (82.8)

12 (34.3)

0.0001

• No ceiling dosage

8 (47.1)

15 (53.6)

19 (65.5)

30 (85.7)

0.05

• No buprenorphine crushing or dilution

15 (88.2)

17 (60.7)

11 (37.9)

17 (48.6)

0.002

Bleach

0 (0.0)

11 (39.3)

11 (37.9)

0 (0.0)

<10 ⁻³

• At least 2 locations/access for bleach inside prison (penitentiary distribution, purchasable inside prison, available in medical unit)

0 (0.0)

20 (71.4)

17 (58.6)

0 (0.0)

<10 ⁻³

• Intelligible information for HR purposes accessible to all prisoners

4 (23.5)

13 (46.4)

12 (41.4)

0 (0.0)

0.30 ł

HBV Vaccination (systematic proposal for unprotected inmates)

0 (0.0)

4 (14.3)

3 (10.3)

18 (51.4)

<10 ⁻³

Post-Exposition Prophylaxis (inmates informed of the availability of PEP)

0 (0.0)

11 (39.3)

1 (3.5)

27 (77.1)

<10 ⁻³

Needle Exchange Programs

0

0

0

0

ARV treatment

14 (82.4)

27 (96.4)

29 (100.0)

33 (94.3)

0.11

• ARV are accessible

17 (100.0)

27 (100.0)

29 (100.00)

33 (89.2)

0.24

• Prescriptions follow national guidelines

14 (82.4)

27 (96.4)

29 (100.0)

33 (94.3)

0.11

Prevention of transmission through tattooing, piercing

2 (11.8)

0 (0.0)

5 (17.2)

0 (0.0)

0.01

Total score, median (Q1-Q3)

4.0 (3.5-4.5)

4.5 (3–6.5)

4.0 (3.0-4.5)

3.5 (2.5-4)

0.0014